Pfizer, Starboard and Bloomberg
Pfizer's board untouched before annual meeting as proxy fight with Starboard rolls on: Bloomberg
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. | Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan.
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe ...
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...
Pfizer, on behalf of its subsidiary Biohaven Pharmaceutical Holding Company, agreed to pay $59,746,277 to resolve allegations that prior to Pfizer's acquisition, Biohaven paid kickbacks to physicians ...
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback